Ignite Creation Date:
2024-05-05 @ 10:39 PM
Last Modification Date:
2024-10-26 @ 10:22 AM
Study NCT ID:
NCT01154335
Status:
COMPLETED
Last Update Posted:
2022-05-03
First Post:
2010-06-29
Brief Title:
Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC
Study Overview
Official Title:
A Phase I Study of Everolimus mTOR Inhibitor and OSI-906 Dual IGFR and IR Tyrosine Kinase Inhibitor for the Treatment of Patients With Refractory Metastatic Colorectal Cancer
Status:
COMPLETED
Status Verified Date:
2022-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the maximum tolerated dose MTD of the combination of OSI-906 and everolimus for the treatment of patients with refractory metastatic colorectal cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None